Facebook
Twitter
LinkedIn
ForwardNCCN 2021 Pharmacy Updates: A Webinar Series
The availability of new therapeutic options and emergence of novel therapies continues to dramatically impact the oncology landscape. The rapid integration of these agents into treatment for various tumor types can be challenging for clinicians. Pharmacists are critical to educating the interprofessional oncology care team about the actions and potential adverse events associated with new and existing therapeutic options. Pharmacists also have an important role in patient education as well as subsequent monitoring and management of treatment-related toxicities.
This program is designed for pharmacists and the oncology care team to review the clinical and patient considerations that influence how to effectively optimize management of patients with various cancer types. Webinars will cover the following topics: pediatric Hodgkin lymphoma, metastatic colorectal cancer, ovarian cancer, transitioning in-patient treatment to the outpatient setting, multiple myeloma, pancreatic adenocarcinoma, prevention of infection in patients with cancer, bladder cancer, adult b-cell lymphomas, soft tissue sarcoma, palliative care, and research pharmacy.
Target Audience
This educational program is designed to meet the educational needs of pharmacists, physicians, nurses, nurse practitioners, physician assistants and other health care professionals who manage patients with cancer.
Learning Objectives
The goal of this project is to ensure that pharmacists, physicians, nurses, nurse practitioners, physician assistants, and other members of the interprofessional oncology care team who manage patients with cancer have the knowledge and skills necessary to:
- Apply the current standards of oncology care and NCCN Clinical Practice Guidelines in Oncology to optimize the management of patients with various cancer types.
- Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with cancer.
- Communicate the importance of a multidisciplinary approach and improve the collaborative performance of the interprofessional oncology care team in the management of patients with cancer.
All live webinars in this series have concluded. The recorded webcasts from this series are listed below.
- New Agents for Soft Tissue Sarcoma and Gastrointestinal Stromal Tumors (held on February 15, 2021, and presented by Sarah E. Hoffman, PharmD, BCOP, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute)
- Updates in the Treatment of Pancreatic Adenocarcinoma (held on March 11, 2021, and presented by Elizabeth Dow-Hillgartner, PharmD, BCPS, BCOP, University of Wisconsin Carbone Cancer Center)
- Updates on Targeted Therapy in the Treatment of Metastatic Colorectal Cancer (held on April 6, 2021, and presented by Michael Leung, PharmD, BCOP, The University of Texas MD Anderson Cancer Center)
- New Developments in the Management of Metastatic Bladder Cancer (held on May 11, 2021, and presented by Diana Cauley, PharmD, BCOP, The University of Texas MD Anderson Cancer Center)
- Novel Agents for the Treatment of Relapsed/Refractory Multiple Myeloma (held on June 9, 2021, and presented by Lindsay Hladnik, PharmD, BCOP, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine)
- Emerging Strategies for Pediatric Hodgkin Lymphoma Treatment (held on June 23, 2021, and presented by Alexis Kuhn, PharmD, BCOP, Mayo Clinic Cancer Center)
- Understanding the Molecular Heterogeneity of Diffuse Large B-Cell Lymphomas and the Place of Targeted Therapies in Treatment (held on August 13, 2021, and presented by Victoria R. Nachar, PharmD, BCOP, University of Michigan Rogel Cancer Center)
- Palliative Care for Patients with Cancer - Symptom Management for Pain and Dyspnea (held on August 27, 2021, and presented by Shelby L. Merchant, PharmD, BCOP, Levine Cancer Institute; and Lauren Koranteng, PharmD, BCPS, Memorial Sloan Kettering Cancer Center)
- Best Practices for Transitioning Oncology Therapies from the Inpatient to the Outpatient Setting (held on September 17, 2021, and presented by Rachel L. McDevitt, PharmD, BCOP, University of Michigan Rogel Cancer Center, and Katherine Tobon, PharmD, BCOP, Moffitt Cancer Center)
- Infection Concerns with Emerging Immune-targeted Treatments in Immunocompromised Patients with Cancer (held on November 4, 2021, and presented by Bernard Marini, PharmD, BCOP, University of Michigan Rogel Cancer Center)
- The Evolving Landscape of Maintenance Therapy for Ovarian Cancer (held on November 30, 2021, and presented by Tyra Gatewood, PharmD, BCOP, Moffitt Cancer Center)
- Current Challenges with Investigational Drug Services and Expanded Access Programs (held on December 16, 2021, and presented by Heidi D. Finnes, PharmD, BCOP, FHOPA, Mayo Clinic Cancer Center, and Stephen R. Polley, PharmD, MPA, MS, BCPS, The Ohio State University Comprehensive Cancer Center)
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care. Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter.
Definitions
NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.
NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Full disclosure of faculty relationships will be made prior to the activity.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates each live activity in this series for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates each educational activity in this series for a maximum of 1.0 contact hour.
Pharmacists
NCCN designates each application-based continuing education activity in this series for 1.0 contact hour (0.10 CEUs) of continuing education credit.
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. Each activity in this series is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Available for an additional fee ($49 per activity): each activity is worth 1 hour of BCOP credit
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% achieved.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.
Price
Please refer to the Schedule tab for dates and times. Check the webinars you would like to attend and click Enroll.
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing